New Targeting in The Reversal of Resistant Glioblastomas (Volume 14) (Cancer Sensitizing Agents for Chemotherapy, Volume 14)

ISBN 10: 0128225270 / ISBN 13: 9780128225271

Published by Academic Press, 2021

About this Item

Seller Inventory # 18379326762

Bibliographic Details

• Title: New Targeting in The Reversal of Resistant Glioblastomas (Volume 14) (Cancer Sensitizing Agents for Chemotherapy, Volume 14)
• Publisher: Academic Press
• Publication Date: 2021
• Language: English
• ISBN 10: 0128225270
• ISBN 13: 9780128225271
• Binding: Hardcover
• Condition: New

About this title

Synopsis

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field.

• Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies
• Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed
• Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma

About the Author

Ali Syed Arbab, MD PHD, is Leader of Tumor Angiogenesis Initiative and Director, Core Imaging Facilities for Small Animals, both at Augusta University. Dr. Arbab’s laboratory is devoted to determining the mechanisms of therapy resistance by focusing on the involvement of bone marrow derived cells in modulating the tumor microenvironment and initiating tumor neovascularization in glioblastoma models. To understand the involvement of bone marrow cells in developing resistance to antiangiogenic therapies (AAT), his group has developed chimeric animal models where bone marrow of the recipient animal is replaced with GFP+ bone marrow. Dr. Arbab’s group documented that tumor-recruited bone marrow cells are a predominantly heterogeneous myeloid cell population that can predict therapeutic response in cancer, and they are using several strategies to target bone marrow or tumor-promoting myeloid cells to potentiate the anti-tumor effect of FDA-approved drugs in preclinical models of glioblastoma.